Observational studyVaccine2026
Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry.
Observational study in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCOVID-19 vaccine clinical trials excluded pregnant women; additional data on safety of COVID-19 vaccines in pregnancy can strengthen clinical recommendations.
objectiveTo assess risk of perinatal death (stillbirth and neonatal death), and preterm birth among women receiving COVID-19 vaccines just prior to or during pregnancy.
methodsThe Centers for Disease Control and Prevention's COVID-19 Vaccine Pregnancy Registry (C19VPR) is an observational cohort of women receiving ≥1 COVID-19 vaccine between December 15, 2020, and June 21, 2021, up to 30 days before their last menstrual period or during pregnancy. Data were collected through interviewer-administered phone surveys. We matched C19VPR pregnancies to 2019 US National Vital Statistics System (NVSS) data based on race, ethnicity, and age group. We estimated week-specific and cumulative risk of perinatal death and preterm birth using a fetuses-at-risk approach among singleton pregnancies ending ≥6 weeks' gestation. For C19VPR participants, pregnancies entered the risk pool at gestational age of vaccination. We compared C19VPR estimates to NVSS using Cox regression to calculate hazard ratios and 95% confidence intervals adjusted for race, ethnicity, age, and pre-pregnancy body mass index. Among C19VPR pregnancies, we used Cox regression to assess difference in risk by vaccine manufacturer.
resultsCumulative risk of perinatal death among C19VPR pregnancies and NVSS were 4.8 and 8.1 per 1000 births, respectively. Cumulative risk of preterm births among C19VPR pregnancies and NVSS were 6.6% and 12.1%, respectively. Adjusted hazard ratios (aHR) suggested lower cumulative risk of perinatal death and preterm birth among C19VPR pregnancies (vaccinated) compared with 2019 NVSS (pre-pandemic estimate) (aHR 0.62 95%CI 0.46, 0.83; aHR 0.55 95%CI 0.51, 0.58, respectively). Within the C19VPR cohort, risks of perinatal death and preterm birth did not differ by vaccine manufacturer.
conclusionWe found no evidence of increased risk of perinatal death or preterm birth after COVID-19 vaccination in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.